Analysis: Regulatory pathway for biosimilars is still unclear

11/2/2010 | Reuters

Although FDA officials have started discussing the creation of a regulatory pathway for approving biosimilars, the agency has not set a deadline for the implementation of such a system, and it could take at least five years for such drugs to reach the market, experts said. "People will be frustrated. It's not going to be a clear pathway for everything," said Ian Spatz, a policy consultant in Washington, D.C., and a former executive at Merck & Co.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC